<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076373</url>
  </required_header>
  <id_info>
    <org_study_id>EpoRepair</org_study_id>
    <secondary_id>2013DR3204</secondary_id>
    <nct_id>NCT02076373</nct_id>
  </id_info>
  <brief_title>Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants</brief_title>
  <acronym>EpoRepair</acronym>
  <official_title>Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants - a Randomized, Double-blind, Placebo-controlled, Prospective, and Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the
      effect of intravenously administered recombinant human erythropoietin (Epo) as compared to
      placebo in preterm infants with brain damage on neurological development until five years od
      age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worldwide, 1% of all infants are born very preterm with less than 32 weeks of gestation,
      which is more than 2 months before expected date of delivery. If these smallest infants
      suffer in addition to prematurity a second hit, such as intraventricular hemorrhage or
      parenchymal infarction, they are at high risk for learning disabilities, mental retardation,
      and cerebral palsy in later life.

      Intraventricular hemorrhage and parenchymal infarction occur in about 12% of very preterm
      infants, mostly in the very smallest and within the first few days after birth, and can be
      recorded by cranial ultrasound. Except for shunt insertion to divert cerebrospinal fluid in
      infants with posthemorrhagic hydrocephalus and possibly the removal of blood clots, there is
      no treatment for established intracerebral bleeding, and no medical therapies exist to
      ameliorate the neurodevelopmental sequelae.

      Apart from stimulating production of red blood cells in the bone marrow, recombinant human
      erythropoietin (Epo) has been shown to exert neuroprotective action in a variety of animal
      models and in clinical studies. Epo administration has been found to be beneficial and safe
      in randomized controlled trials (RCT) involving adult and infant patients.

      Observational data suggest that Epo administered to very preterm infants in order to prevent
      from anemia improves long-term cognitive outcomes until school-age especially in those
      infants who had suffered intracerebral bleeding. These data, however, are observational and
      therefore do not allow for any firm conclusions or recommendations. The hypothesis generated
      by these data calls for confirmation or refutation by an RCT designed to address this
      question.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>5 years</time_frame>
    <description>With 5 years of age, composite intelligence quotient to be assessed by standardized IQ tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker cranial MRI</measure>
    <time_frame>40 weeks postmenstrual age</time_frame>
    <description>Brain injury score assessed on cranial MRI, including brain maturation score and white matter and gray matter injury scores, as biomarker for long-term neurodevelopmental outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Infants will be followed for the duration of hospital stay, an expected average of 14 weeks</time_frame>
    <description>Analysis will be performed to get insight about the distributions of adverse events and other safety relevant outcomes between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>2 years</time_frame>
    <description>Bayley Scales of Infant Development (BSID-III) and the presence or absence of impairment of motor function (cerebral palsy) and neurosensory function (blindness or deafness) will be assessed with 18 to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker serial cranial ultrasound</measure>
    <time_frame>Infants will be followed for the duration of hospital stay, an expected average of 14 weeks</time_frame>
    <description>Cranial ultrasound is a useful point of care method to detect, confirm and monitor brain damage including intracerebral bleeding. It is part of clinical routine for the duration of hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall developmental outcome</measure>
    <time_frame>5 years</time_frame>
    <description>Neurological and formal psychological examination. Normal Overall developmental outcome is classified as normal if IQ &gt;84 and without one or more of the following: motor impairment, cognitive impairment, behavior problems, poor general health, severe hearing loss, or bilateral blindness.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Course of intracerebral bleeding</measure>
    <time_frame>Infants will be followed for the duration of hospital stay, an expected average of 14 weeks</time_frame>
    <description>Course of intracerebral bleeding from onset until term equivalent age with additional visits at 28 days of life and 36 weeks postmenstrual age.
No remaining lesions as recorded by cranial ultrasound
Persisting posthemorrhagic hydrocephalus without any drainage
Persisting posthemorrhagic hydrocephalus with repetitive but transient csf-drainage
Posthemorrhagic hydrocephalus with permanent csf-drainage
Convulsions and other abnormalities or medications related to intracerebral bleeding</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intraventricular Hemorrhage of Prematurity</condition>
  <arm_group>
    <arm_group_label>recombinant human Erythropoietin (Epo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.
In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.
In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human Erythropoietin</intervention_name>
    <description>i.v. administration</description>
    <arm_group_label>recombinant human Erythropoietin (Epo)</arm_group_label>
    <other_name>Epoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>i.v. administration</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infants with less than 32 weeks of gestation and/or less than 1500 g weight at birth

          2. Intraventricular hemorrhage and/or hemorrhagic parenchymal infarction

          3. Less than 8 days of life

          4. Informed written parental consent

        Exclusion Criteria:

          1. Genetically defined syndrome

          2. Severe congenital malformation adversely affecting life expectancy and/or
             neurodevelopment

          3. A priory palliative care

          4. Unlikely to participate at 5-year follow-up examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>31 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Wellmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Ulrich Bucher, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven Wellmann, MD</last_name>
    <phone>+41442555340</phone>
    <email>sven.wellmann@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Rüegger, MD</last_name>
    <phone>+41442555342</phone>
    <email>christoph.rueegger@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>katrin Klebermaß-Schrehof, MD</last_name>
      <phone>+4314040032320</phone>
      <email>katrin.klebermass-schrehof@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité University Medical Center</name>
      <address>
        <city>Berlin</city>
        <zip>13344</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christof Dame, MD, PhD</last_name>
      <phone>+49 30 450 566122</phone>
      <email>christof.dame@charite.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Bührer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Fuchs, MD</last_name>
      <phone>+4976127043000</phone>
      <email>hans.fuchs@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Roland Hentschel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Koch, MD</last_name>
      <phone>+4970712984742</phone>
      <email>Alexander.Koch@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Christian F Poets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Meyer Schiffer, MD</last_name>
      <phone>+41 62 838 4948</phone>
      <email>philipp.meyer@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Philipp Meyer Schiffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Basel (UKBB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Severin M Kasser, MD</last_name>
      <phone>+41 61 7041212</phone>
      <email>severin.kasser@ukbb.ch</email>
    </contact>
    <investigator>
      <last_name>Sven M Schulzke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Gerull, MD</last_name>
      <phone>+41 31 632 1403</phone>
      <email>roland.gerull@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Nelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Scharrer, MD</last_name>
      <phone>+41 81 256 6406</phone>
      <email>brigitte.scharrer@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Bär, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anita Truttmann, MD</last_name>
      <phone>+41213143447</phone>
      <email>Anita.Truttmann@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Jean-François Tolsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital</name>
      <address>
        <city>St. Gallen</city>
        <zip>9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjarte Rogdo, MD</last_name>
      <phone>+41 71 494 1867</phone>
      <email>Bjarte.Rogdo@kispisg.ch</email>
    </contact>
    <investigator>
      <last_name>Bjarte Rogdo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Knöpfli, Ms</last_name>
      <phone>+41442555342</phone>
      <email>claudia.knoepfli@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cornelia Hagmann, MD</last_name>
      <phone>+41442555342</phone>
      <email>cornelia.hagmann@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Claude Fauchere, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.eporepair.ch</url>
    <description>EpoRepair trial homepage</description>
  </link>
  <reference>
    <citation>Rüegger CM, Hagmann CF, Bührer C, Held L, Bucher HU, Wellmann S; EpoRepair Investigators. Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants (EpoRepair). Neonatology. 2015;108(3):198-204. doi: 10.1159/000437248. Epub 2015 Aug 8.</citation>
    <PMID>26278911</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

